Radical Numerics applies AI-designed bacteriophage to humans

Summary

Radical Numerics, an AI laboratory founded in California in 2025, announced that it has administered an AI-designed bacteriophage to a patient. The design, based on the T7 phage and featuring an AI-modified gp17 tail fiber protein, is claimed to be the first AI-generated product to reach a human. Its foundation model, Omnii-1, is described as the largest multimodal genomic model to date. The model processes 28 different types of biological data to generate functional phage candidates.

Why it matters

Antimicrobial resistance is expected to cause approximately 40 million deaths by 2050. Traditional phage hunting from environmental collections takes months and often fails. If AI can reduce this search time to days while maintaining high functional efficiency (4.8% versus 69.9% for random edits), it is reshaping the economics of personalized anti-infective treatment. The phage is explicitly positioned as a platform demo. Applications include cancer vaccines, identifying genes for rare diseases, and detecting biological threats.

Highlights

• 69.9% of the phage variants recommended by the AI were functional; in random edits of similar scale, this rate was 4.8%. Of the 6,694 active variants, 2,161 performed better than the original T7 phage.
• CEO Eric Nguyen is a former member of the Stanford/Arc Institute team that designed the first fully AI-generated phage genomes. Nguyen aims to reduce treatment selection time from months to a few days. The first phage genomes for this design were created in August 2026.
• Phage therapy remains a small market. The market size, which was $1.27 billion in 2025, is expected to reach $1.86 billion by 2035 with a compound annual growth rate of 3.91%. This indicates that clinical adoption is progressing slowly despite the urgency of the problem.

Critical take

This announcement is merely a claim based on a single patient, has not undergone peer review, and clinical outcomes have not been disclosed. The FDA expanded access pathway cited by the company is not mentioned in its own technical report. The report only vaguely refers to 'appropriate state regulators.' Until independent verification and full clinical data are available, this remains an unverified medical result and continues to be a corporate press release.